HEART TRANSPLANTATION Pediatric Recipients 2010 ISHLT J Heart Lung Transplant. 2010 Oct; 29 (10): 1083-1141.

Slides:

Advertisements

Similar presentations

HEART TRANSPLANTATION

Advertisements

OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.

2002 ISHLT HEART TRANSPLANTATION Pediatric Recipients.

HEART-LUNG TRANSPLANTATION Overall ISHLT 2006 J Heart Lung Transplant 2006;25:

2002 ISHLT HEART TRANSPLANTATION Overall ISHLT NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR * Numbers may be low due to delayed reporting. Number.

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:

HEART-LUNG TRANSPLANTATION Overall ISHLT 2005 J Heart Lung Transplant 2005;24:

HEART TRANSPLANTATION Overall ISHLT 2006 J Heart Lung Transplant 2006;25:

HEART TRANSPLANTATION Overall ISHLT 2008 J Heart Lung Transplant 2008;27:

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:

2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Pediatric Recipients.

2002 ISHLT J Heart Lung Transplant 2002; 21: HEART TRANSPLANTATION Overall.

J Heart Lung Transplant 2009;28: LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2009.

2002 ISHLT J Heart Lung Transplant 2002; 21: HEART-LUNG TRANSPLANTATION Overall.

2004 ISHLT J Heart Lung Transplant 2004; 23: HEART-LUNG TRANSPLANTATION Overall.

2001 THE REGISTRY OF THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION: EIGHTEENTH ANNUAL REPORT.

J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Overall ISHLT 2009.

HEART TRANSPLANTATION Overall ISHLT 2007 J Heart Lung Transplant 2007;26:

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27:

2004 ISHLT J Heart Lung Transplant 2004; 23: LUNG TRANSPLANTATION Pediatric Recipients.

J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Pediatric Recipients ISHLT 2009.

2003 ISHLT J Heart Lung Transplant 2003; 22: HEART TRANSPLANTATION Overall.

HEART-LUNG TRANSPLANTATION

2003 ISHLT J Heart Lung Transplant 2003; 22: LUNG TRANSPLANTATION Pediatric Recipients.

2003 ISHLT J Heart Lung Transplant 2003; 22: HEART TRANSPLANTATION Pediatric Recipients.

2003 ISHLT J Heart Lung Transplant 2003; 22: HEART-LUNG TRANSPLANTATION Overall.

LUNG TRANSPLANTATION Pediatric Recipients 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

2001 J Heart Lung Transplant 2001; 20: ; 2002: 21: THE REGISTRY OF THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION: EIGHTEENTH.

HEART-LUNG TRANSPLANTATION Overall ISHLT 2008 J Heart Lung Transplant 2008;27:

2002 ISHLT J Heart Lung Transplant 2002; 21: HEART TRANSPLANTATION Pediatric Recipients.

HEART TRANSPLANTATION

HEART-LUNG TRANSPLANTATION Overall 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

LUNG TRANSPLANTATION Overall 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:

HEART-LUNG TRANSPLANTATION

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2005 J Heart Lung Transplant 2005;24:

2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Overall.

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27:

HEART TRANSPLANTATION Overall ISHLT 2005 J Heart Lung Transplant 2005;24:

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26.

HEART-LUNG TRANSPLANTATION

HEART TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):

LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):

HEART-LUNG TRANSPLANTATION Overall 2014 JHLT Oct; 33(10):

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

HEART TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

Optimizing lung transplant outcomes in the adult and pediatric patient. Cynthia S. Herrington, MD Associate Professor of Surgery Keck School of Medicine.

HEART-LUNG TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

SSA Hearing on Compassionate Allowances Janet N Scheel MD November 9,2010.

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

HEART TRANSPLANTATION Pediatric Recipients JHLT Oct; 32(10):

HEART-LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):

HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):

LUNG TRANSPLANTATION Adult Recipients 2014 JHLT Oct; 33(10):

HEART-LUNG TRANSPLANTATION Pediatric Recipients 2015 JHLT Oct; 34(10):

The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;

The Registry of the International Society for Heart and Lung Transplantation: Twenty- seventh official adult heart transplant report—2010 Josef Stehlik,

Number of transplants, by donor type figure 8.1

The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report—2014; Focus Theme: Retransplantation

HEART-LUNG TRANSPLANTATION

HEART TRANSPLANTATION

HEART TRANSPLANTATION

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010

HEART-LUNG TRANSPLANTATION

HEART-LUNG TRANSPLANTATION

HEART-LUNG TRANSPLANTATION

HEART TRANSPLANTATION

HEART-LUNG TRANSPLANTATION

A: Comparison of pediatric lung transplant survival between different age groups. A: Comparison of pediatric lung transplant survival between different.

HEART-LUNG TRANSPLANTATION

Presentation transcript:

HEART TRANSPLANTATION Pediatric Recipients 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

AGE DISTRIBUTION OF PEDIATRIC HEART RECIPIENTS (Transplants: January June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

AGE DISTRIBUTION FOR DONORS OF PEDIATRIC HEART RECIPIENTS (Transplants: January June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

AGE DISTRIBUTION OF PEDIATRIC HEART RECIPIENTS By Year of Transplant NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as evidence that the number of hearts transplanted worldwide has increased and/or decreased in recent years ISHLT J Heart Lung Transplant Oct; 29 (10):

NUMBER OF CENTERS REPORTING PEDIATRIC HEART TRANSPLANTS 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

NUMBER OF CENTERS REPORTING PEDIATRIC HEART TRANSPLANTS 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

AVERAGE CENTER VOLUME AND PERCENTAGE OF TRANSPLANTS BY CENTER VOLUME Pediatric Heart Transplants: January 1, June 30, ISHLT J Heart Lung Transplant Oct; 29 (10):

DISTRIBUTION OF TRANSPLANTS BY CENTER VOLUME Pediatric Heart Transplants: January 1, June 30, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RE-TRANSPLANTS By Transplant Year Re-transplants: January 1994 – December 2008 Only patients who were less than 18 years old at the time of re-transplant are included ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RE-TRANSPLANTS By Inter-transplant Interval Re-transplants: January June 2009 Only patients who were less than 18 years old at the time of re-transplant are included. Analysis is based on the age at the time of re-transplant 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

KAPLAN-MEIER SURVIVAL RATES FOR PEDIATRIC HEART RETRANSPLANTS STRATIFIED BY INTER-TRANSPLANT INTERVAL Re-transplants: January June 2008 Only patients who were less than 18 years old at the time of re-transplant are included ISHLT J Heart Lung Transplant Oct; 29 (10):

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS (Age: < 1 Year) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS ( Age: 1-10 Years ) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS ( Age: Years ) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival (Transplants: 1/1982-6/2008) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Conditional Kaplan-Meier Survival (Transplants: 1/1982-6/2008) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Conditional Kaplan-Meier Survival for Recent Era (Transplants: 1/1999-6/2008) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2008) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2008) Age: < 1 Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2008) Age: 1-10 Years 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982-6/2008) Age: Years 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS: AVERAGE CENTER VOLUME DISTRIBUTION BY LOCATION Transplants between January 2000 and June ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Patient vs. Graft Survival (Transplants: 1/1999-6/2008) Average Center Volume: 1-4 Transplants per Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Patient vs. Graft Survival (Transplants: 1/1999-6/2008) Average Center Volume: 5-9 Transplants per Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Patient vs. Graft Survival (Transplants: 1/1999-6/2008) Average Center Volume: Transplants per Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS: AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS: DIAGNOSIS DISTRIBUTION BY LOCATION Transplants between January 2000 and June ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS: DONOR AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors For 1 Year Mortality N=3,838 Reference diagnosis = cardiomyopathy 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Borderline Significant Risk Factors For 1 Year Mortality N=3, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality N=3, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient Age N=3,838 NOTE: The impact of age should be considered in the context of height and diagnosis+age ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Recipient Height N=3,838 NOTE: The impact of height should be considered in the context of age and diagnosis+age ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Donor Age N=3, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Pre-Transplant Creatinine N=3, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality Ischemia Time N=3, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Factors Not Significant for 1 Year Mortality Recipient Factors: IV inotropes, sternotomy, history of malignancy, hospitalized, diabetes Donor Factors: Gender, clinical infection, history of diabetes Transplant Factors: CMV mismatch, HLA mismatch, center volume 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = <1 Years Risk Factors For 1 Year Mortality N=1,009 Reference diagnosis = congenital without PGE or ECMO 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = <1 Years Borderline Significant Risk Factors For 1 Year Mortality N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = <1 Years Risk Factors for 1 Year Mortality N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = <1 Years Ischemia Time N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = <1 Years Pre-Transplant Creatinine N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = <1 Years Center Volume for Pediatric Transplants N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = <1 Years Recipient Height N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = 1-10 Years Risk Factors For 1 Year Mortality N=1,448 Reference diagnosis = cardiomyopathy 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = 1-10 Years Borderline Significant Risk Factors For 1 Year Mortality N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = 1-10 Years Risk Factors for 1 Year Mortality N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = 1-10 Years Pre-Transplant Creatinine N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = 1-10 Years Recipient Height N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = 1-10 Years Recipient Bilirubin N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = Years Risk Factors For 1 Year Mortality N=1,381 Reference diagnosis = cardiomyopathy 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = Years Borderline Significant Risk Factors For 1 Year Mortality N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Age = Years Risk Factors for 1 Year Mortality N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1996-6/2008) Risk Factors for 1 Year Mortality in Age = Years Ischemia Time N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors For 5 Year Mortality N=2,420 Reference diagnosis = cardiomyopathy 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Borderline Significant Risk Factors For 5 Year Mortality N=2, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality N=2, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality Recipient Age N=2,420 NOTE: The impact of age should be considered in the context of height and diagnosis+age ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality Recipient Height N=2,420 NOTE: The impact of height should be considered in the context of age and diagnosis+age ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality Donor Age N=2, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality Center Volume for Pediatric Transplants N=2, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality Ischemia Time N=2, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2003) Risk Factors for 5 Year Mortality BSA Ratio N=2, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/1998) Risk Factors For 10 Year Mortality N=910 Reference diagnosis = cardiomyopathy * Impact should be considered in context of donor age and recipient BSA shown in subsequent figures ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/1998) Borderline Significant Risk Factors For 10 Year Mortality N=910 Reference diagnosis = cardiomyopathy 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/1998) Risk Factors for 10 Year Mortality N= ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/1997) Risk Factors for 10 Year Mortality Donor Age N= ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/1997) Risk Factors for 10 Year Mortality Recipient BSA N= ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/1997) Risk Factors for 10 Year Mortality Pre-Transplant Creatinine N= ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/1997) Risk Factors for 10 Year Mortality Center Volume for Pediatric Transplants N= ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (1/1995-6/2000) Factors Not Significant for 10 Year Mortality Recipient Factors: PRA, diabetes, repeat transplant, transfusions, hospitalized, PGE, VAD, bilirubin Donor Factors: Cause of death, weight, height, age, clinical infection Transplant Factors: Ischemia time, CMV mismatch 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (7/1997-6/2004) Risk Factors for the Development of CAV within 5 Years N=1,470 Reference diagnosis = cardiomyopathy 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (7/1997-6/2004) Borderline Significant Risk Factors for the Development of CAV within 5 Years N=1,470 Reference diagnosis = cardiomyopathy 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (7/1997-6/2004) Risk Factors for the Development of CAV within 5 Years N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (7/1997-6/2004) Risk Factors for the Development of CAV within 5 Years Donor Height N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTS (7/1997-6/2004) Risk Factors for the Development of CAV within 5 Years Center Volume of All Age Transplants N=1, ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Cross-Sectional Analysis Functional Status of Surviving Recipients (Follow-ups: April June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Longitudinal Analysis Functional Status of Surviving Recipients (Follow-ups: April June 2009) For the Same Patients 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: April June 2009) Age: <1 Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: April June 2009) Age: 1-10 Years 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: April June 2009) Age: Years 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: March June 2009) US Recipients Only 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: April June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Induction Immunosuppression (Transplants: January June 2009) Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Induction Immunosuppression (Transplants: January June 2009) Test of increasing trend over time: Any induction p < Polyclonal p < IL2 p < Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2008) Conditional on Survival to 14 Days 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group and Treated Rejection Between Transplant Discharge and 1-Year Follow-up (1-Year Follow-ups: July June 2008) Conditional on Survival to 1 Year Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2008) Conditional on Survival to 14 Days Age: < 1 Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2008) Conditional on Survival to 14 Days Age: 1-10 Years 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2008) Conditional on Survival to 14 Days Age: Years 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up (Follow-ups: January June 2009) NOTE: Different patients are analyzed in Year 1 and Year 5 % of Patients Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up for Same Patients at Each Time Point (Follow-ups: January June 2009) Analysis is limited to patients who were alive at the time of the follow-up 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January June 2009) Analysis is limited to patients who were alive at the time of the follow-up NOTE: Different patients are analyzed in Year 1 and Year ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Prednisone Use Conditional on Survival to 1 Year (Transplants: June 2008) Survival (%) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Prednisone Use for a Recent Era Conditional on Survival to 1 Year (Transplants: January 1998 – June 2008) Survival (%) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Stratified by Tacrolimus vs. Cyclosporine Use at Discharge (Transplants: January June 2008) Conditional on Survival to 14 Days Survival (%) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Stratified by Tacrolimus vs. Cyclosporine Use Conditional on Survival to 1 Year (Transplants: January June 2008) Survival (%) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Conditional on survival to 1 year (1-Year Follow-ups: July June 2008) Survival (%) Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Stratified by Calcineurin Use at Discharge Conditional on survival to 1 year (1-Year Follow-ups: July June 2008) Survival (%) Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Stratified by Calcineurin Use at Discharge: Age = 0-10 Years Conditional on survival to 1 year (1-Year Follow-ups: July June 2008) Survival (%) Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Treated Rejection within 1 st Year Stratified by Calcineurin Use at Discharge: Age = Years Conditional on survival to 1 year (1-Year Follow-ups: July June 2008) Survival (%) Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS EXPERIENCING ACUTE REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP Stratified by Induction (Follow-ups: July June 2009) % experiencing acute rejection within 1 year Overall: p = Overall< FemaleMale Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS EXPERIENCING ACUTE REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP Stratified by Type of Induction (Follow-ups: July June 2009) % experiencing acute rejection within 1 year No comparisons were statistically significant at Overall< FemaleMale Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS EXPERIENCING ACUTE REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP Stratified by Maintenance Immunosuppression and Induction (Follow-ups: July June 2009) % experiencing acute rejection within 1 year Overall: all comparisons were statistically significant at 0.05 except CyA + no induction vs. CyA + induction and TAC + no induction vs. TAC + induction <1 year: CyA + no induction vs. TAC + no induction ( p=0.0268); 1-10 years: all comparisons were statistically significant at 0.05 except CyA + no induction vs. CyA + induction and TAC + no induction vs. TAC + induction years: CyA + no induction vs. TAC + no induction (p = ); CyA + induction vs. TAC + no induction (p < ); CyA + induction vs. TAC + induction ( p =0.0025) Overall< Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti- rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS EXPERIENCING ACUTE REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP Stratified by Maintenance Immunosuppression ( Follow-ups: July June 2009 ) % experiencing acute rejection within 1 year Overall: all comparisons were statistically significant at 0.05 except CyA +MMF vs. CyA +AZA and TAC + MMF vs. TAC + AZA. <1: CyA + MMF vs. TAC + MMF (p =0.0076). 1-10: CyA + MMF vs. TAC + MMF (p = ); CyA + AZA vs. TAC + MMF (p=0.0007) : all comparisons were statistically significant at 0.05 except CyA +MMF vs. CyA +AZA TAC + MMF vs. TAC + AZA. Overall< Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti- rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS EXPERIENCING ACUTE REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP Stratified by Calcineurin Inhibitor Use at Discharge ( Follow-ups: July June 2009) % experiencing acute rejection within 1 year Overall: CyA vs. TAC (p < ) <1: CyA vs. TAC (p=0.0356) 1-10: CyA vs. TAC (p < ) 11-17: CyA vs. TAC (p < ) Overall< Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: April June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: April June 2009) Stratified by Induction 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: June 2009) Stratified by Tacrolimus vs. Cyclosporine Use Conditional on Survival to 1 Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: April June 2009) Stratified by Age Group 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: January 1999-June 2009) Stratified by Age Group 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients ( Follow-ups: April June 2009) Stratified by Ischemia Time 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients ( Follow-ups: January June 2009) Stratified by Ischemia Time for Recent Era 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients ( Follow-ups: April June 2009) Stratified by Ischemia Time and Recipient Age 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

GRAFT SURVIVAL FOLLOWING REPORT OF CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: April June 2009) Stratified by Age Group 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM SEVERE RENAL DYSFUNCTION* For Pediatric Heart Recipients (Follow-ups: April June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM SEVERE RENAL DYSFUNCTION* For Pediatric Heart Recipients (Follow-ups: June 2009) Stratified by Tacrolimus vs. Cyclosporine Use Conditional on Survival to 1 Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM RENAL REPLACEMENT THERAPY* For Pediatric Heart Recipients (Follow-ups: April June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

MALIGNANCY POST-HEART TRANSPLANTATION FOR PEDIATRICS Cumulative Prevalence in Survivors (Follow-ups: April June 2009) Malignancy/Type1-Year Survivors 5-Year Survivors 10-Year Survivors No Malignancy 3,684 (98.2%)1,521 (94.9%)411 (92.6%) Malignancy (all types combined) 69 (1.8%)82 (5.1%)33 (7.4%) Malignancy Type Lymph Other 463 Skin 11 Type Not Reported 1 NOTE: Multiple types may be reported; sum of types may be greater than total number with malignancy ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM MALIGNANCY For Pediatric Heart Recipients (Follow-ups: April June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM MALIGNANCY For Pediatric Heart Recipients (Follow-ups: April June 2009) Stratified by Tacrolimus vs. Cyclosporine Use Conditional on Survival to 1 Year 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

FREEDOM FROM LYMPHOMA For Pediatric Heart Recipients (Follow-ups: April June 2009) Stratified by Induction 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Incidence of Hypertension between 1 and 3 Years (Transplants: April June 2006) Maintenance Immunosuppression at discharge and 1 year % HTN reported between 1 and 3 years P-value For Patients on drug For Patients not on drug Azathioprine Cyclosporine MMF Prednisone <.0001 Rapamycin Tacrolimus ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Incidence of Hypertension between 3 and 8 Years (Transplants: April June 2001) Maintenance Immunosuppression at discharge and 1 year % HTN reported between 3 and 8 years P-value For Patients on drug For Patients not on drug Azathioprine Cyclosporine MMF Prednisone <.0001 Rapamycin Tacrolimus ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART RECIPIENTS Relationship of Rejection and Coronary Artery Vasculopathy (Follow-ups: July 2004 – June 2009) Rejection During 1 st Year Reported CAV between 1 st and 3 rd years post-transplant YesNoAll Yes9 5.1% % % No9 3.4% % % p = ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January June 2009) CAUSE OF DEATH 0-30 Days (N = 475) 31 Days - 1 Year (N = 443) >1 Year - 3 Years (N = 318) >3 Years - 5 Years (N = 246) >5 Years - 10 Years (N = 371) >10 Years (N = 197) CORONARY ARTERY VASCULOPATHY 5 (1.1%)30 (6.8%)62 (19.5%)72 (29.3%)105 (28.3%)54 (27.4%) ACUTE REJECTION 45 (9.5%)108 (24.4%)75 (23.6%)35 (14.2%)46 (12.4%)12 (6.1%) LYMPHOMA 1 (0.2%)9 (2.0%)12 (3.8%)8 (3.3%)35 (9.4%)15 (7.6%) MALIGNANCY, OTHER 4 (0.9%)2 (0.6%)2 (0.8%)5 (1.3%)10 (5.1%) CMV 1 (0.2%)12 (2.7%)1 (0.3%) INFECTION, NON-CMV 55 (11.6%)68 (15.3%)21 (6.6%)8 (3.3%)18 (4.9%)18 (9.1%) PRIMARY FAILURE 108 (22.7%)24 (5.4%)10 (3.1%)16 (6.5%)21 (5.7%)7 (3.6%) GRAFT FAILURE 101 (21.3%)51 (11.5%)64 (20.1%)60 (24.4%)76 (20.5%)49 (24.9%) TECHNICAL 27 (5.7%)3 (0.7%)2 (0.6%)3 (1.2%)4 (1.1%)2 (1.0%) OTHER 23 (4.8%)26 (5.9%)32 (10.1%)24 (9.8%)34 (9.2%)10 (5.1%) MULTIPLE ORGAN FAILURE 48 (10.1%)56 (12.6%)10 (3.1%)7 (2.8%)10 (2.7%)10 (5.1%) RENAL FAILURE 1 (0.2%)5 (1.1%)1 (0.3%)1 (0.4%)1 (0.3%)3 (1.5%) PULMONARY 29 (6.1%)31 (7.0%)16 (5.0%)8 (3.3%)9 (2.4%)5 (2.5%) CEREBROVASCULAR 31 (6.5%)16 (3.6%)10 (3.1%)2 (0.8%)7 (1.9%)2 (1.0%) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January June 2009) CAUSE OF DEATH 0-30 Days (N = 226) 31 Days - 1 Year (N = 266) >1 Year - 3 Years (N = 202) >3 Years - 5 Years (N = 173) >5 Years - 10 Years (N = 306) >10 Years (N =190) CAV 2 (0.9%)14 (5.3%)33 (16.3%)46 (26.6%)84 (27.5%)52 (27.4%) ACUTE REJECTION 23 (10.2%)53 (19.9%)40 (19.8%)27 (15.6%)37 (12.1%)12 (6.3%) LYMPHOMA 6 (2.3%)7 (3.5%)6 (3.5%)29 (9.5%)15 (7.9%) MALIGNANCY, OTHER 1 (0.4%)1 (0.5%)1 (0.6%)4 (1.3%)9 (4.7%) CMV 8 (3.0%)1 (0.5%) INFECTION, NON- CMV 27 (11.9%)34 (12.8%)12 (5.9%)3 (1.7%)14 (4.6%)16 (8.4%) PRIMARY FAILURE 50 (22.1%)10 (3.8%)4 (2.0%)7 (4.0%)13 (4.2%)7 (3.7%) GRAFT FAILURE 35 (15.5%)31 (11.7%)50 (24.8%)51 (29.5%)68 (22.2%)47 (24.7%) TECHNICAL 14 (6.2%)2 (1.0%)1 (0.6%)4 (1.3%)2 (1.1%) OTHER 17 (7.5%)21 (7.9%)27 (13.4%)17 (9.8%)30 (9.8%)10 (5.3%) MULTIPLE ORGAN FAILURE 29 (12.8%)43 (16.2%)9 (4.5%)6 (3.5%)8 (2.6%)10 (5.3%) RENAL FAILURE 5 (1.9%)1 (0.5%)1 (0.6%)1 (0.3%)3 (1.6%) PULMONARY 11 (4.9%)28 (10.5%)11 (5.4%)6 (3.5%)8 (2.6%)5 (2.6%) CEREBROVASCULAR 18 (8.0%)12 (4.5%)4 (2.0%)1 (0.6%)6 (2.0%)2 (1.1%) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

PEDIATRIC HEART TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2009) 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):